Introduction: The Inflammation-Diabetes Axis and the Search for Reliable Biomarkers

Diabetes mellitus, a global health crisis affecting over 537 million adults, is fundamentally a metabolic disorder marked by chronic hyperglycemia arising from defects in insulin secretion, insulin action, or both. Beyond glucose dysregulation, it is now widely recognized that a state of low-grade, persistent inflammation—often termed metaflammation—plays a pivotal role in the pathogenesis of both type 1 and type 2 diabetes. This chronic inflammatory milieu drives insulin resistance, impairs beta‑cell function, and accelerates the development of devastating complications such as cardiovascular disease, nephropathy, and neuropathy. Consequently, identifying biomarkers that accurately reflect this underlying inflammatory burden has become a priority for improving risk stratification, early diagnosis, and therapeutic monitoring. While established markers like C‑reactive protein (CRP), interleukin‑6 (IL‑6), and tumor necrosis factor‑alpha (TNF‑α) provide useful information, they lack the specificity and mechanistic relevance required for personalized diabetes care. In this context, serum progranulin has emerged as a promising candidate that bridges inflammation, adiposity, and glucose metabolism.

Understanding Serum Progranulin: Structure, Sources, and Biological Functions

Progranulin (PGRN) is a 68‑kDa glycoprotein composed of 7.5 granulin domains. It is encoded by the GRN gene and is expressed in a wide variety of tissues, including epithelial cells, immune cells (macrophages, neutrophils), adipocytes, and neurons. Unlike many cytokines, progranulin is produced as a full‑length precursor that can be cleaved by extracellular proteases (e.g., matrix metalloproteinases and neutrophil elastase) into smaller granulin peptides (granulins A–G). These cleavage products often exhibit opposing biological activities: the full‑length protein generally exerts anti‑inflammatory and growth‑promoting effects, while the granulin peptides can promote inflammation.

The primary known functions of progranulin encompass:

  • Cell growth and wound healing: PGRN stimulates proliferation and migration of fibroblasts and endothelial cells, accelerating tissue repair.
  • Regulation of inflammation: Full‑length progranulin can bind directly to tumor necrosis factor receptors (TNFRs), competing with TNF‑α and thereby blunting pro‑inflammatory signaling. Conversely, granulin peptides can activate toll‑like receptor 9 (TLR9) and promote cytokine release, creating a nuanced regulatory loop.
  • Adipose tissue biology: Adipocytes produce progranulin in proportion to adiposity. In obesity, progranulin expression in visceral fat is elevated, and it is thought to contribute to adipose tissue inflammation and insulin resistance.
  • Neuronal survival: In the central nervous system, progranulin protects against neurodegeneration; mutations in GRN cause frontotemporal dementia.

Given its dual role in both promoting and resolving inflammation, the net effect of circulating progranulin depends on the tissue context, the local protease environment, and the overall balance between full‑length and cleaved forms. In metabolic disease, however, most clinical studies have associated elevated serum progranulin levels with increased inflammatory markers, making it a reliable reflection of systemic inflammation.

Progranulin and Insulin Resistance

Insulin resistance is the hallmark of prediabetes and type 2 diabetes. Adipose tissue dysfunction in obesity leads to ectopic lipid accumulation, hypoxia, and recruitment of pro‑inflammatory immune cells, particularly macrophages. Progranulin is released abundantly from these activated macrophages and from hypertrophic adipocytes. Once in the circulation, progranulin can directly interfere with insulin signaling. Studies in adipocytes and hepatocytes have shown that recombinant progranulin reduces insulin‑stimulated glucose uptake and impairs phosphorylation of Akt and insulin receptor substrate‑1 (IRS‑1). Mechanistically, this occurs partly through induction of suppressor of cytokine signaling 3 (SOCS3), a negative regulator of insulin receptor signaling. Thus, elevated progranulin not only signals inflammation but actively perpetuates insulin resistance.

Progranulin and Beta‑Cell Function

The integrity and function of pancreatic beta‑cells are critical for maintaining glucose homeostasis. Chronic exposure to pro‑inflammatory cytokines (e.g., IL‑1β, IFN‑γ) induces beta‑cell apoptosis and reduces insulin secretion. Progranulin has been detected in pancreatic islets, and its expression is upregulated under glucolipotoxic conditions. Some evidence suggests that progranulin may have a protective role in beta‑cells by activating the Akt survival pathway, yet prolonged high levels could contribute to immune‑mediated destruction. In type 2 diabetes, beta‑cell mass declines gradually; the net effect of progranulin on beta‑cell fate likely depends on the stage of disease and concomitant inflammatory milieu. Paradoxically, in type 1 diabetes, progranulin may modulate autoimmunity; one study found that children with newly diagnosed type 1 diabetes had lower serum progranulin than controls, possibly reflecting a compensatory attempt to limit inflammation.

Progranulin and Diabetic Complications

Chronic inflammation and oxidative stress drive the micro‑ and macrovascular complications of diabetes. Elevated serum progranulin has been consistently associated with:

  • Cardiovascular disease: Progranulin levels correlate with carotid intima‑media thickness, coronary artery calcification, and the risk of major adverse cardiac events. The protein promotes endothelial dysfunction, increases vascular smooth muscle cell proliferation, and destabilizes atherosclerotic plaques by attracting macrophages.
  • Diabetic nephropathy: Higher circulating progranulin is linked to albuminuria, declining eGFR, and renal fibrosis. In podocytes, progranulin can activate the Notch pathway, leading to injury.
  • Diabetic retinopathy: In patients with proliferative retinopathy, vitreous and serum progranulin are markedly elevated, and the protein may stimulate retinal neovascularization.
  • Non‑alcoholic fatty liver disease (NAFLD): Given the close relationship between diabetes and NAFLD, progranulin levels are elevated in steatohepatitis and correlate with liver fibrosis.

These associations underscore the potential of serum progranulin as a multi‑complication risk marker in diabetes.

Research Findings: Clinical Evidence Linking Serum Progranulin to Inflammation and Diabetes

Epidemiological Studies

Numerous cross‑sectional and prospective studies have examined serum progranulin concentrations in patients with type 2 diabetes compared to healthy controls. A meta‑analysis published in 2022 (including over 2000 participants) confirmed that type 2 diabetes patients have significantly higher progranulin levels, with a standardized mean difference of approximately 0.8. Moreover, progranulin levels were positively correlated with fasting glucose, HbA1c, HOMA‑IR (insulin resistance index), and body mass index (Cytokine 2022). Interestingly, the association remained significant after adjusting for obesity, suggesting an inflammation‑specific contribution beyond adiposity.

Progranulin and Inflammatory Markers

A key observation is the positive correlation between serum progranulin and CRP (r = 0.3–0.6 across studies). In a cohort of 450 participants with type 2 diabetes, those in the highest quartile of progranulin had CRP levels three‑fold higher than those in the lowest quartile, independent of age and smoking. Progranulin also correlates with IL‑6, TNF‑α, and fibrinogen. These findings position progranulin as a robust marker of the systemic inflammatory state in diabetes.

Predictive Value for Diabetic Complications

Several longitudinal studies have evaluated whether baseline progranulin predicts future complications. In a 10‑year follow‑up of the EURODIAB Prospective Complications Study, each standard deviation increase in serum progranulin was associated with a 25% higher risk of incident cardiovascular disease (Diabetes Care 2023). Similarly, in patients with diabetic nephropathy, progranulin levels predicted progression to end‑stage renal disease even after adjustment for eGFR and albuminuria. These data support the clinical utility of progranulin as a prognostic biomarker.

Progranulin in Type 1 Diabetes

Although most research has focused on type 2 diabetes, emerging evidence indicates that serum progranulin is lower in type 1 diabetes compared to age‑matched controls. This may reflect the autoimmune nature of the disease: in type 1 diabetes, the balance between pro‑ and anti‑inflammatory signals is skewed toward the Th1/Th17 axis, and the reduced progranulin might represent a loss of an anti‑inflammatory counter‑regulatory mechanism. Moreover, in children with type 1 diabetes, progranulin levels correlate inversely with HbA1c, suggesting a potential protective effect. However, these observations require confirmation in larger cohorts.

Progranulin as a Therapeutic Target

Given its involvement in insulin resistance and inflammation, progranulin is being explored as a drug target. Preclinical studies have shown that neutralizing progranulin antibodies improve insulin sensitivity and reduce adipose tissue inflammation in obese mice (Nature Communications 2019). Conversely, recombinant full‑length progranulin administration exacerbated insulin resistance in diet‑induced obese models. These findings highlight the complex, context‑dependent role of progranulin. Currently, no progranulin‑targeted therapies have entered clinical trials for diabetes, but the preclinical data are sufficiently compelling to warrant further investigation. Small molecule inhibitors of the granulin‑TNFR interaction or modulators of progranulin processing could represent future strategies.

Clinical Implications: Integrating Serum Progranulin into Diabetes Care

Enhanced Risk Stratification

Currently, clinicians rely on CRP and conventional lipid profiles to gauge inflammation in diabetes. Adding serum progranulin measurement could improve the identification of patients with residual inflammatory risk—those who, despite achieving glycemic targets, remain at elevated risk of complications. A combined biomarker panel (e.g., progranulin + CRP + IL‑6) might offer superior predictive accuracy. However, standardizing assays and establishing reference ranges across different populations (age, sex, ethnicity, BMI) is a prerequisite.

Personalized Treatment Monitoring

Certain glucose‑lowering therapies have been shown to modulate progranulin levels. For example, metformin reduces serum progranulin in patients with type 2 diabetes, an effect that correlates with improvements in HOMA‑IR. GLP‑1 receptor agonists and SGLT2 inhibitors, both of which have anti‑inflammatory properties, also decrease progranulin. Measuring progranulin before and after treatment initiation could help assess the anti‑inflammatory efficacy of these medications and guide therapy selection for individuals with a high inflammatory phenotype.

Potential for Early Detection

Progranulin levels are elevated in individuals with prediabetes compared to normoglycemic controls, and they correlate with the progression from prediabetes to overt diabetes. This raises the possibility of using serum progranulin as an early warning marker, perhaps in combination with fasting glucose and HbA1c, to identify those who would benefit most from intensive lifestyle intervention or pharmacological prevention.

Future Directions: Unresolved Questions and Research Priorities

Standardization and Assay Development

Before serum progranulin can enter clinical practice, large‑scale efforts must define normal ranges. Currently, available ELISA kits show variability depending on the antibody specificity for full‑length versus cleaved forms. Moreover, progranulin is present in plasma and serum; binding to complement proteins may affect measurement. International consensus on a reference standard, similar to the CRP WHO standard, is needed.

Understanding Tissue‑Specific Roles

Most clinical studies measure circulating progranulin, but its local tissue concentration and effects may differ. Advanced imaging or tissue biopsy studies could illuminate how adipose, liver, and pancreatic progranulin relate to systemic levels. Furthermore, the balance between full‑length progranulin and granulin peptides in different compartments is poorly characterized. Future research should incorporate measurement of both forms to understand their differential contribution to diabetes pathophysiology.

Longitudinal Intervention Trials

While observational data are robust, interventional studies that modify progranulin levels (e.g., by lifestyle, pharmacotherapy, or targeted biologics) and measure outcomes are needed to establish causality. If a reduction in progranulin is shown to delay or reverse complications, it would strengthen the case for progranulin as a therapeutic target and a treatment‑response biomarker.

Integration with Multi‑Omics

Diabetes is a heterogeneous disease. Combining progranulin with genetic (GRN variants), epigenetic, proteomic, and metabolomic data could uncover distinct inflammatory endotypes. For example, individuals with a specific polymorphism in the GRN promoter (rs5848) have altered progranulin levels and may have different diabetes risk profiles. Such integrative approaches will advance precision diabetes medicine.

Comparative Perspective: Progranulin versus Other Inflammatory Biomarkers

Biomarker Primary Source Association with Diabetes Strengths Limitations
Progranulin Adipocytes, macrophages Strong with insulin resistance, complications Direct link to adipocyte inflammation; dual (pro‑/anti‑) regulatory role Assay variability; cleavage products complicate interpretation
hs‑CRP Liver (IL‑6 driven) Moderate with cardiovascular risk Standardized assay; widely available; low cost Non‑specific; not mechanistically tied to insulin signaling
IL‑6 Immune cells, adipose Strong with insulin resistance Key driver of acute phase response High diurnal variability; short half‑life
TNF‑α Macrophages, adipocytes Strong with insulin resistance Direct role in insulin receptor desensitization Unstable in blood; low circulating levels
Adiponectin Adipocytes Inverse with insulin resistance Anti‑inflammatory; well‑studied Negative correlation complicates interpretation

As the table illustrates, progranulin occupies a unique niche: it is produced at the intersection of immune cells and adipocytes, and it directly influences TNF‑α signaling while showing independent associations with diabetic complications. When measured alongside adiponectin, progranulin can provide a more complete picture of the adipose‑immune axis in diabetes.

Conclusion

Serum progranulin has matured from an obscure growth factor to a compelling biomarker reflecting the inflammatory state that underlies diabetes and its complications. The convergent evidence from cross‑sectional studies, prospective cohorts, and mechanistic experiments supports its use for risk stratification, prognostic assessment, and potentially therapeutic targeting. However, the field must address critical gaps: standardization of assays, deeper understanding of its tissue‑specific proteolytic processing, and confirmation through randomized intervention trials. If these challenges are met, serum progranulin could become a routine component of the diabetes biomarker repertoire, helping to guide personalized anti‑inflammatory strategies and ultimately improve long‑term outcomes for millions of patients worldwide.